163 related articles for article (PubMed ID: 37064293)
1. Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation.
Hughes D; Lenny A; Shah K; Longworth L; Devercelli G; Ayodele O
J Health Econ Outcomes Res; 2023; 10(1):80-88. PubMed ID: 37064293
[No Abstract] [Full Text] [Related]
2. Estimating health state utilities in primary hyperoxaluria type 1: a valuation study.
de Freitas HM; Danese D; Hubig L; Lloyd A; Lombardelli S
J Med Econ; 2023; 26(1):386-393. PubMed ID: 36852648
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom.
Hubig L; Sussex AK; MacCulloch A; Hughes D; Graham R; Morris L; Raza S; Lloyd AJ; Sowinski A; Gallop K
J Health Econ Outcomes Res; 2023; 10(1):41-50. PubMed ID: 36883056
[No Abstract] [Full Text] [Related]
4. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
Che M; Pullenayegum E
Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
[TBL] [Abstract][Full Text] [Related]
5. Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States.
Lo SH; Lloyd A; Elkhalifa S; Sisic Z; van Nooten FE
Pharmacoecon Open; 2022 Mar; 6(2):231-239. PubMed ID: 34532843
[TBL] [Abstract][Full Text] [Related]
6. A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease.
Hadi M; Swinburn P; Nalysnyk L; Hamed A; Mehta A
Orphanet J Rare Dis; 2018 Sep; 13(1):159. PubMed ID: 30201003
[TBL] [Abstract][Full Text] [Related]
7. Defining Utility Values for Chorea Health States in Patients with Huntington's Disease.
Claassen DO; Ayyagari R; Goldschmidt D; Zhou M; Leo S; Ribalov R
Adv Ther; 2022 Apr; 39(4):1784-1793. PubMed ID: 35195860
[TBL] [Abstract][Full Text] [Related]
8. Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD).
Matza LS; Stewart KD; Fournier M; Rowen D; Lachmann R; Scarpa M; Mengel E; Obermeyer T; Ayik E; Laredo F; Pulikottil-Jacob R
Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38409492
[TBL] [Abstract][Full Text] [Related]
9. Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan.
Takumoto Y; Sasahara Y; Narimatsu H; Murata T; Akazawa M
Health Econ Rev; 2022 Dec; 12(1):63. PubMed ID: 36564539
[TBL] [Abstract][Full Text] [Related]
10. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS).
Matza LS; Phillips GA; Howell TA; Ciffone N; Ahmad Z
J Med Econ; 2020 Sep; 23(9):978-984. PubMed ID: 32479143
[No Abstract] [Full Text] [Related]
11. Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.
Sundaram M; Smith MJ; Revicki DA; Miller LA; Madhavan S; Hobbs G
Pharmacoeconomics; 2010; 28(3):201-16. PubMed ID: 20151725
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Eliciting health state utilities for Aromatic L-amino Acid Decarboxylase (AADC) deficiency: a UK vignette study.
Smith AB; Hanbury A; Buesch K
J Patient Rep Outcomes; 2021 Dec; 5(1):130. PubMed ID: 34897562
[TBL] [Abstract][Full Text] [Related]
14. Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).
Williams K; Gibson A; McNamara L; Jones T; Lloyd AJ
J Med Econ; 2020 Oct; 23(10):1142-1150. PubMed ID: 32644862
[TBL] [Abstract][Full Text] [Related]
15. Elicitation of Health State Utility Values in Retinitis Pigmentosa by Time Trade-off in the United Kingdom.
O'Brien P; Enstone A; Bridge D; Wyn R; Banhazi J
Clinicoecon Outcomes Res; 2023; 15():29-39. PubMed ID: 36687800
[TBL] [Abstract][Full Text] [Related]
16. Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France.
Smith AB; Hanbury A; Beitia Ortiz de Zarate I; Hammes F; de Pouvourville G; Buesch K
Patient Relat Outcome Meas; 2021; 12():237-246. PubMed ID: 34285619
[TBL] [Abstract][Full Text] [Related]
17. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
18. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
Lo SH; Lloyd A; Marshall J; Vyas K
Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
[TBL] [Abstract][Full Text] [Related]
19. Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations.
Matza LS; Stewart KD; Lloyd AJ; Rowen D; Brazier JE
Value Health; 2021 Jun; 24(6):812-821. PubMed ID: 34119079
[TBL] [Abstract][Full Text] [Related]
20. Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.
Johnston K; Stoffman JM; Mickle AT; Klaassen RJ; Diles D; Olatunde S; Eliasson L; Bahar R
Patient Prefer Adherence; 2021; 15():1407-1417. PubMed ID: 34194224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
